Mesoblast (MESO) News Today $7.40 -0.02 (-0.27%) (As of 07/26/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 November 2021 October 2021 September 2021 August 2021 Time Period July 26 at 7:10 AM | americanbankingnews.comMesoblast (NASDAQ:MESO) Upgraded to Overweight at Piper SandlerJuly 24 at 5:24 PM | marketbeat.comMesoblast (NASDAQ:MESO) Stock Price Down 5.2%Mesoblast (NASDAQ:MESO) Trading Down 5.2%July 23 at 4:45 PM | marketwatch.comMesoblast's Gets FDA Acceptance of Application for Allogeneic Cellular TherapyJuly 23 at 4:45 PM | finance.yahoo.comFDA accepts Mesoblast’s latest BLA for paediatric GvHD cell therapyJuly 23 at 2:46 PM | marketbeat.comMesoblast (NASDAQ:MESO) Lifted to "Overweight" at Piper SandlerPiper Sandler raised shares of Mesoblast from a "neutral" rating to an "overweight" rating and boosted their price target for the company from $4.00 to $11.00 in a report on Tuesday.July 23 at 1:24 PM | marketbeat.comMesoblast (NASDAQ:MESO) Trading Up 7.3%Mesoblast (NASDAQ:MESO) Trading Up 7.3%July 23 at 7:53 AM | globenewswire.comFDA Accepts Mesoblast's Biologics License Application (BLA) for Ryoncil® in Children With Steroid-Refractory Acute Graft-Versus-Host Disease (SR-aGVHD)July 23 at 6:53 AM | marketwatch.comMesoblast Shares Rise on Start of Late-Stage Trial For Low Back Pain TreatmentJuly 22, 2024 | finanznachrichten.deMesoblast Limited: Patient Enrollment Commenced in Pivotal Phase 3 Trial of Rexlemestrocel-L for Chronic Low Back PainJuly 22, 2024 | msn.comUp 308% in 6 months, why is the Mesoblast share price tumbling today?July 22, 2024 | finance.yahoo.comMesoblast begins subject enrolment in Phase III back pain treatment trialJuly 21, 2024 | globenewswire.comPatient Enrollment Commenced in Pivotal Phase 3 Trial of Rexlemestrocel-L for Chronic Low Back PainJuly 21, 2024 | americanbankingnews.comMesoblast (NASDAQ:MESO) Shares Gap Up to $7.10July 21, 2024 | americanbankingnews.comMesoblast Limited (NASDAQ:MESO) Receives Average Rating of "Hold" from BrokeragesJuly 8, 2024 | globenewswire.comMesoblast Resubmits Biologics License Application (BLA) with United States Food & Drug Administration (FDA) for Approval of Ryoncil® in Children with Steroid-Refractory Acute Graft-Versus-Host Disease (SR-aGVHD)July 2, 2024 | marketbeat.comPenbrook Management LLC Sells 150,175 Shares of Mesoblast Limited (NASDAQ:MESO)Penbrook Management LLC lowered its stake in Mesoblast Limited (NASDAQ:MESO - Free Report) by 54.5% during the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 125,175 shares of the company's stock after selling 150,175 shares duringJuly 1, 2024 | globenewswire.comMesoblast to File Biologics License Application for Ryoncil® FDA Approval Next WeekJune 27, 2024 | marketbeat.comMesoblast (NASDAQ:MESO) Shares Up 4.2%Mesoblast (NASDAQ:MESO) Trading 4.2% HigherJune 26, 2024 | marketbeat.comMesoblast Limited (NASDAQ:MESO) Given Average Rating of "Hold" by AnalystsShares of Mesoblast Limited (NASDAQ:MESO - Get Free Report) have been given a consensus rating of "Hold" by the six analysts that are presently covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and two have asJune 20, 2024 | marketbeat.comMesoblast (NASDAQ:MESO) Rating Reiterated by Cantor FitzgeraldCantor Fitzgerald reaffirmed an "overweight" rating on shares of Mesoblast in a report on Thursday.June 13, 2024 | marketbeat.comMesoblast Limited (NASDAQ:MESO) Sees Large Drop in Short InterestMesoblast Limited (NASDAQ:MESO - Get Free Report) saw a significant decrease in short interest in the month of May. As of May 31st, there was short interest totalling 500,800 shares, a decrease of 36.0% from the May 15th total of 781,900 shares. Based on an average daily trading volume, of 2,230,000 shares, the days-to-cover ratio is currently 0.2 days.June 5, 2024 | marketbeat.comMesoblast (NASDAQ:MESO) Shares Down 3.3% Mesoblast (NASDAQ:MESO) Trading Down 3.3%June 4, 2024 | marketbeat.comMesoblast (NASDAQ:MESO) Shares Up 3%Mesoblast (NASDAQ:MESO) Stock Price Up 3%June 2, 2024 | globenewswire.comMesoblast Corporate Presentation at Investor ConferenceJune 1, 2024 | marketbeat.comMesoblast Limited (NASDAQ:MESO) Receives Average Recommendation of "Hold" from BrokeragesShares of Mesoblast Limited (NASDAQ:MESO - Get Free Report) have earned a consensus recommendation of "Hold" from the six ratings firms that are covering the company, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation, three have given a hold recommendMay 28, 2024 | msn.comASX 200 ‘drifts off’ after ‘weaker-than-expected’ retail sales numbersMay 27, 2024 | msn.comOvercoming long-term unemployment by getting physically and mentally fit to join the workforceMay 23, 2024 | marketbeat.comMesoblast (NASDAQ:MESO) Shares Gap Up to $7.89Mesoblast (NASDAQ:MESO) Shares Gap Up to $7.89May 17, 2024 | marketbeat.comMesoblast (NASDAQ:MESO) Trading Up 5.4%Mesoblast (NASDAQ:MESO) Trading Up 5.4%May 16, 2024 | msn.com‘Best day for the market this year’: ASX 200 rises 1.65 per centMay 13, 2024 | marketbeat.comMesoblast (NASDAQ:MESO) Shares Gap Down to $7.36Mesoblast (NASDAQ:MESO) Shares Gap Down to $7.36May 8, 2024 | marketbeat.comMesoblast (NASDAQ:MESO) Trading Down 7.9%Mesoblast (NASDAQ:MESO) Trading Down 7.9%May 3, 2024 | msn.comIf you invested $8,000 in Mesoblast shares at the beginning of 2024, guess how much you'd have now!May 2, 2024 | msn.comASX 200 closes down 1.23 per cent on WednesdayMay 1, 2024 | marketbeat.comMesoblast (NASDAQ:MESO) Stock Price Up 10.2%Mesoblast (NASDAQ:MESO) Trading Up 10.2%May 1, 2024 | msn.comAustralia stocks lower at close of trade; S&P/ASX 200 down 1.23%April 30, 2024 | marketbeat.comStockNews.com Upgrades Mesoblast (NASDAQ:MESO) to "Hold"StockNews.com upgraded Mesoblast from a "sell" rating to a "hold" rating in a report on Tuesday.April 30, 2024 | marketbeat.comMesoblast (NASDAQ:MESO) Shares Gap Down to $7.10Mesoblast (NASDAQ:MESO) Shares Gap Down to $7.10April 30, 2024 | msn.comYen falls after suspected intervention on Monday, eyes on FedApril 30, 2024 | msn.comWhy is the Mesoblast share price taking a dive on Tuesday?April 29, 2024 | globenewswire.comAppendix 4c Quarterly Activity Report for Quarter Ended March 31, 2024April 29, 2024 | msn.comSoft landing remains within reach as consumer spending spree set for breather: UBSApril 29, 2024 | msn.comStablecoin Tether is losing market share - reportApril 29, 2024 | msn.comUS Dollar Uptrend on Thin Ice as Fed Takes Center Stage This WeekApril 29, 2024 | marketbeat.comMesoblast (NASDAQ:MESO) Shares Gap Up to $6.24Mesoblast (NASDAQ:MESO) Shares Gap Up to $6.24April 23, 2024 | marketbeat.comMesoblast (NASDAQ:MESO) Trading Up 9.4%Mesoblast (NASDAQ:MESO) Trading Up 9.4%April 22, 2024 | marketbeat.comMesoblast (NASDAQ:MESO) Shares Gap Up to $5.21Mesoblast (NASDAQ:MESO) Shares Gap Up to $5.21April 17, 2024 | marketbeat.comMesoblast (NASDAQ:MESO) Stock Price Up 7.9%Mesoblast (NASDAQ:MESO) Shares Up 7.9%April 16, 2024 | msn.comInsiders are buying Mesoblast and these ASX sharesApril 12, 2024 | marketbeat.comMesoblast Limited (NASDAQ:MESO) Given Consensus Recommendation of "Hold" by BrokeragesShares of Mesoblast Limited (NASDAQ:MESO - Get Free Report) have been assigned a consensus recommendation of "Hold" from the six research firms that are presently covering the company, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, three have assi Get Mesoblast News Delivered to You Automatically Sign up to receive the latest news and ratings for MESO and its competitors with MarketBeat's FREE daily newsletter. Email Address Automatic Income (from home) (Ad)Everyone’s talking about this new income hack that could generate triple digit returns on your money. But here’s the best part… Watch this short video MESO Media Mentions By Week MESO Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. MESO News Sentiment▼0.360.62▲Average Medical News Sentiment MESO News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. MESO Articles This Week▼173▲MESO Articles Average Week Get Mesoblast News Delivered to You Automatically Sign up to receive the latest news and ratings for MESO and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: MRUS News Today XENE News Today MLTX News Today SWTX News Today MOR News Today ARVN News Today PTGX News Today DCPH News Today CPRX News Today AMPH News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:MESO) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredCollapse of the PetrodollarThe death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Ru...Colonial Metals | SponsoredRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED w...Behind the Markets | SponsoredMust-See: Elon’s New Invention is Absolutely InsaneCould Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredElon to Transform U.S. Economy? A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” ...Porter & Company | Sponsored5 Stocks that could triple in a week Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Mesoblast Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Mesoblast With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free MESO Stock Alerts